

QUANTUM HEALTHCARE LIMITED
(Company Registration No. 202218645W)
(Incorporated in Singapore)

- I. **PROPOSED PLACEMENT OF AN AGGREGATE 2,727,272,800 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY;**
 - II. **PROPOSED CONVERSION OF DEBT INTO 1,595,912,182 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY; AND**
 - III. **PROPOSED DIRECTORS' FEES CAPITALISATION OF AN AGGREGATE S\$275,239.20 OUTSTANDING DIRECTORS' FEES OWED AND PAYABLE TO CERTAIN PRESENT AND FORMER DIRECTORS IN PARTIAL SETTLEMENT OF THEIR OUTSTANDING DIRECTORS' FEES**
- **LAPSE OF LQN AND ENTRY INTO SUPPLEMENTAL AGREEMENT**
-

Unless otherwise defined, all capitalised terms used herein shall have the meanings ascribed to them in the Previous Announcements (as defined below).

1. INTRODUCTION

The board of directors ("**Board**") of Quantum Healthcare Limited ("**Company**") refers to the Company's announcements dated:

- (a) 22 September 2025 and 24 September 2025 in relation to the Proposed Placement, Proposed PW Debt Conversion and Proposed Directors' Fees Capitalisation; and
- (b) 6 October 2025 in relation to the receipt of the listing and quotation notice of the Placement Shares, PW Debt Conversion Shares, and Directors' Fees Capitalisation Shares on the Catalist, subject to, *inter alia*, the Company's compliance with the SGX-ST's listing requirements.

(collectively, the "**Previous Announcements**").

2. LAPSE OF LQN

Further to the Previous Announcements, the Board wishes to update Shareholders that as the Company is unable to allot and issue the Placement Shares to the Placees by 15 October 2025, the LQN granted by SGX-ST on 6 October 2025 has lapsed. The Proposed Placement could not be completed by 15 October 2025 as *inter alia*, the opening of the CDP Securities Account of one of the Placees required for the crediting of the Placement Shares has not yet been completed, and the Placees have also notified the Company that they require more time to complete their due diligence on the Group.

3. ENTRY INTO SUPPLEMENTAL AGREEMENT

In connection with the above, the Company and the Placees have, on 20 October 2025, entered into a supplemental agreement ("**Supplemental Agreement**") to vary the terms of the Placement Agreement as set out below.

Pursuant to the Supplemental Agreement:

- (a) the Parties have agreed to extension of the completion date of the Proposed Placement to take place on 30 November 2025 ("**Extended Completion Date**");

- (b) the Placees agree to undertake to pay the Company a non-refundable deposit of S\$300,000 within one (1) business day from the date of execution of the Supplemental Agreement (“**Non-Refundable Deposit**”) where, *inter alia*:
 - (i) the Non-Refundable Deposit shall be treated as a deposit or advance towards payment of the Placement Proceeds due for the Placement Shares in the event Completion of the Proposed Placement takes place; or
 - (ii) the Company shall be entitled to retain the Non-Refundable Deposit in its entirety, should the Placees (or any of them) delay or default in completing the subscription for their relevant proportion of the Placement Shares on or prior to the Extended Completion Date for any reason whatsoever;
- (c) the Company agrees to return the Non-Refundable Deposit to the Placees in the event the re-submission of the application for the listing and quotation of the Placement Shares is rejected by the SGX-ST and no listing and quotation notice is granted in relation thereto; and
- (d) in the event the Non-Refundable Deposit is retained by the Company, the Parties shall be released and discharged from their respective obligations and liabilities under the Placement Agreement, and there shall be no claims by any party against the other for any cost, damages, compensation or otherwise arising from the non-completion of the Proposed Placement.

Save as disclosed above and the amendments in relation thereto, all other terms and conditions of the Placement Agreement remain unchanged and are in full force and effect.

4. FURTHER ANNOUNCEMENTS

The Company will make further announcements as and when there are material developments on the Proposed Placement, the Placement Shares, the Proposed PW Debt Conversion, the PW Debt Conversion Shares, the Proposed Directors’ Fees Capitalisation, the Directors’ Fees Capitalisation Shares, the Company and/or its subsidiaries.

5. CAUTIONARY STATEMENT

As at the date of this announcement, Shareholders should be cautioned that there is no assurance that the Proposed Placement, Proposed PW Debt Conversion and Proposed Directors’ Fees Capitalisation will proceed or proceed on the present terms.

Shareholders are advised to read this announcement and any further announcements by the Company carefully. Shareholders are advised to refrain from taking any action in respect of their Shares which may be prejudicial to their interests, and to exercise caution when dealing in their Shares. In the event of any doubt, Shareholders should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

By Order of the Board
QUANTUM HEALTHCARE LIMITED

Thomas Tan Gim Chua
Chief Executive Officer and Executive Director
20 October 2025

*This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (“**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**Exchange**”) and the Exchange assumes no responsibility for the contents of this*

announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.